Search PubMed⌕ Search

Biomedical subjects

M SERAGLIA

Publications and source records attributed to M SERAGLIA.

11 recordsLinked to original sources
PubMed1963

EFFECT OF ACETAZOLAMIDE AND TRIPLE SULFONAMIDE ON CITRATE AND CALCIUM EXCRETION.

The administration of acetazolamide was shown to increase the excretion of calcium in both normal persons and in stone formers, while at the same time the urinary excretion of citrate was reduced. Urinary citrate is potentially of importance in chelating calcium and preventing it from precipitating. In view of the chemical similarity between acetazolamide and the sulfonamides it was considered that the latter might produce a similar effect, with potential hazard if administered to a stone former. This was shown not to be the case.

Acetazolamide↗
PubMed1963

CRIS DE COEUR.

Explore the source record for details and available documents.

Humans↗
PubMed1963

URINARY EXCRETION OF CALCIUM AND CITRATE IN NORMAL INDIVIDUALS AND STONE FORMERS WITH VARIATION IN CALCIUM INTAKE.

The changes which occur in both calcium and citrate excretion in normal persons, in idiopathic calcium stone formers and in persons with hyperparathyroidism have been measured at high and low levels of dietary calcium intake. The findings suggested a difference in the renal handling of calcium between normal subjects and stone formers. There was a greater increase in the urinary excretion of calcium with increased intake of calcium in individuals with renal calculi than in normals. Increasing the calcium intake shifted the mole ratio of calcium to citrate unfavourably for the chelation of calcium by citrate, and this unfavourable shift was more marked in the stone formers than in normal individuals. These findings support the concept that urinary citrate may be of importance in the prevention of calcium precipitation and hence in the pathogenesis of kidney stones.

Calcium↗
PubMed1963

EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE.

Spironolactone was evaluated as a diuretic in the therapy of six patients with chronic severe congestive heart failure, during which metabolic balance studies were performed. Two of the patients showed a clear-cut although moderate diuresis and natriuresis in response to spironolactone in the presence of other diuretics. Two patients had slight unsustained responses and two showed no response. No significant change in potassium excretion was observed. A decrease in the serum sodium level was noted in four patients, associated with a rise in serum potassium. Urinary aldosterone excretion was normal or low in all patients and showed no correlation with the diuretic response to spironolactone.It is concluded that spironolactone has definite but limited usefulness in the therapy of some but not all patients with chronic congestive heart failure.

Aldosterone↗